{
    "clinical_study": {
        "@rank": "116168", 
        "arm_group": {
            "arm_group_label": "Oral Vancomycin", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is twofold. First, is to determine whether vancomycin is effective\n      in the early treatment of Biliary Atresia (BA) and Primary Sclerosing Cholangitis (PSC), and\n      if so, by what mechanism. Secondly, to characterize human intestinal microbial communities\n      and their interactions with the host."
        }, 
        "brief_title": "Treating Primary Sclerosing Cholangitis and Biliary Atresia With Vancomycin", 
        "condition": [
            "Primary Sclerosing Cholangitis", 
            "Biliary Atresia"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Biliary Atresia", 
                "Cholangitis", 
                "Cholangitis, Sclerosing"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Persons who have primary sclerosing cholangitis, biliary atresia, a chronic\n             intestinal disorder or who are undergoing upper or lower endoscopy.\n\n          -  Persons who have primary sclerosing cholangitis or biliary atresia who are good\n             candidates for vancomycin therapy.\n\n        Exclusion Criteria:\n\n          -  Patients that have taken antibiotics and/or immunomodulators within the last 3 months\n             will be excluded as this will alter the original bacterial flora.\n\n          -  Females who are pregnant may not participate."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "40 Years", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "200", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 12, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02137668", 
            "org_study_id": "Davies 1"
        }, 
        "intervention": {
            "arm_group_label": "Oral Vancomycin", 
            "intervention_name": "Oral Vancomycin", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Vancomycin"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 12, 2014", 
        "location": {
            "contact": {
                "last_name": "Yinka Davies, MD", 
                "phone": "916-332-1244"
            }, 
            "facility": {
                "address": {
                    "city": "Sacramento", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "95841"
                }, 
                "name": "Sacramento Pediatric Gastroenterology"
            }, 
            "investigator": {
                "last_name": "Yinka Davies, M.D.", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "The Human Gastrointestinal Tract Microbiota in the Setting of Treating Primary Sclerosing Cholangitis and Biliary Atresia With Vancomycin", 
        "overall_official": {
            "affiliation": "Sacramento Pediatric Gastroenterology", 
            "last_name": "Yinka Davies, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "May 2018", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Blood tests, imaging studies and/or liver biopsy changes before and while on oral vancomycin will determine the benefit of the treatment.", 
            "measure": "Determine the benefit of oral vancomycin therapy for Primary Sclerosing Cholangitis and Biliary Atresia", 
            "safety_issue": "No", 
            "time_frame": "3 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02137668"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Sacramento Pediatric Gastroenterology", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Sacramento Pediatric Gastroenterology", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2010", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}